CurrentCapital BluecrossPolicy MP 2.345

Subcutaneous Hormone Pellet Implants

Policy governing coverage and medical necessity for subcutaneous estradiol and testosterone implantable pellets for Capital BlueCross members, specifying indications considered medically necessary versus investigational and associated guideline requirements.

Policy Summary

PayerCapital Bluecross

PolicySubcutaneous Hormone Pellet Implants

Policy CodePolicy MP 2.345

Change TypeNo material change

Effective DateOct 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of at least two early‑morning total serum testosterone levels below the laboratory reference range or <300 ng/dL to establish medical necessity for implantable testosterone pellets.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalEstradiol pellets

Medically necessaryTestosterone pellets

300 ng/dLTestosterone threshold

14 yrsDelayed puberty cutoff

11980, J3490, S0189

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Procedure codes listed

Coverage and Medical Necessity Criteria

Medically Necessary Indications (Testosterone pellets)

Covered when ANY ONE of the following diagnoses/clinical situations is met:

Medically necessary indications for testosterone pellets: Delayed male puberty (see Policy Guidelines for age criteria) ; OR Hypogonadotropic hypogonadism (congenital or acquired) with low serum testosterone (e.g., idiopathic gonadotropin or LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation) ; OR Primary hypogonadism (congenital or acquired) with low serum testosterone (e.g., testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy/radiation, or toxic damage) ; OR Female-to-male gender reassignment (see MP 1.144 for surgical guidance).See Policy Guidelines: diagnostic testosterone criteria (two early-morning total serum testosterone levels below the laboratory reference range or <300 ng/dL; one level <150 ng/dL sufficient for severe deficiency) and delayed puberty age criteria

Follow Endocrine Society/American Urological Association guidance for testing and monitoring; pellet dosing typical adult range 150–450 mg subcutaneously; repeat administration may be necessary to maintain levels

Investigational / Not Medically Necessary

Not covered / investigational uses include, but are not limited to:

Investigational / not medically necessary uses: Subcutaneous estradiol (estrogen) pellets (investigational and not covered); OR Use of implantable testosterone pellets for indications without clear pathologic hypogonadism such as age-related low testosterone (aging/idiopathic) ; OR Treatment of sexual dysfunction (e.g., erectile dysfunction, decreased libido) in men or women ; OR Use for post-menopausal symptoms, pain management in women, depression, or athletic performance enhancement.N/A

Insufficient evidence to support improved health outcomes; ACOG does not support testosterone pellets for post‑menopausal symptoms; no FDA‑approved estradiol pellet formulations in the U.S.

Coverage stance

Policy coverage statements:

Testosterone implant coverage: Subcutaneous implantable testosterone pellets (Testopel pellets) are covered when medically necessary.

Medical necessity determination is based on member benefits and eligibility; prior authorization required to establish medical necessity and supporting laboratory documentation is recommended.

Estradiol implant coverage: Subcutaneous estradiol pellets are considered investigational and are not covered.

No FDA‑approved implantable estradiol pellet formulations; safety and release-rate concerns noted.

The American College of Obstetricians and Gynecologists (ACOG) advises against using testosterone pellets for post‑menopausal symptoms and recommends alternatives to pellet therapy because of limited safety data and the inability to remove a pellet once implanted. The policy aligns with ACOG’s position and notes there are no FDA‑approved estradiol pellet formulations available in the U.S.; estradiol pellet preparations have produced unpredictable serum concentrations and have documented safety concerns, including infection, bleeding, and difficulties with reversibility. Consequently, practitioners should follow shared decision‑making and prefer other delivery methods when treating menopausal symptoms.

For testosterone pellets, the policy distinguishes approved clinical scenarios from investigational uses. Implantable testosterone pellets (Testopel) are recognized as medically necessary only for specified diagnoses such as delayed male puberty, hypogonadotropic hypogonadism (congenital or acquired), primary hypogonadism (congenital or acquired), and female‑to‑male gender reassignment — with required laboratory confirmation and monitoring per Policy Guidelines.

Androgen deficiency that is attributed to normal aging or idiopathic hypogonadism without an identifiable disorder of the testicles, pituitary gland, or brain is not covered. The ICD‑10 descriptions included in the policy (for example, E23.0 and E29.1) explicitly note that androgen deficiency due to aging or idiopathic causes is excluded from coverage.

More broadly, uses of implantable hormone pellets that lack demonstrated benefit are considered investigational and may be denied. Examples of investigational or not medically necessary scenarios include treatment of sexual dysfunction in men or women (e.g., erectile dysfunction, decreased libido), management of pain in women, post‑menopausal symptom relief with estradiol pellets, depression, and enhancement of athletic performance.

Providers should exercise caution when considering pellet implantation for indications that do not meet clear diagnostic criteria for hypogonadism. The FDA has stated that testosterone therapy should be prescribed only for men with low testosterone caused by specific medical conditions and confirmed by laboratory testing; use for age‑related low testosterone is not supported. Pellet implantation is less flexible for dose adjustment than other formulations, increasing the importance of ensuring a clearly documented medical indication and appropriate baseline laboratory evidence before proceeding.

When the clinical picture suggests age‑related symptoms without objective biochemical hypogonadism, pellet therapy is considered investigational and should not be used as routine therapy for aging‑related low testosterone or nonspecific symptoms.

Subcutaneous estradiol pellets are investigational and not covered. The policy states there is insufficient evidence to conclude that implantation of estradiol pellets improves health outcomes, and explicitly lists subcutaneous estradiol pellets as an investigational, non‑covered service.

Claims submitted for estradiol pellet implantation may be denied on this basis; providers should use FDA‑approved and guideline‑endorsed estrogen delivery methods for indications such as menopausal symptom management.

Procedure, Diagnosis, and Dosing Codes

Referenced product/dosingmixed

Testopel 75 mg pellets

Testosterone implant formulation described (75mg testosterone per pellet)

Procedure Codesmixed

11980	Procedure code listed for subcutaneous implant
J3490	Miscellaneous drug code (listed)
S0189	HCPCS code listed for implantable testosterone pellets

ICD-10-CM Diagnosis CodesICD-10

E23.0	Hypopituitarism [hypothalamic hypogonadism] [not covered for androgen deficiency due to aging or idiopathic hypogonadism not due to disorders of the testicles, pituitary gland or brain]
E29.1	Testicular hypofunction [primary] [not covered for androgen deficiency due to aging or idiopathic hypogonadism not due to disorders of the testicles, pituitary gland or brain]
E30.0	Delayed puberty [congenital or acquired endogenous androgen absence]
E89.5	Postprocedural testicular hypogonfunction
F64.0	Transsexualism

Total serum testosterone diagnostic threshold

Diagnostic requirementTwo early-morning total serum testosterone levels obtained on different days below the testing laboratory's normal reference range or <300 ng/dL

Exception for severe deficiencyOne early-morning total serum testosterone level <150 ng/dL is sufficient to indicate severe deficiency

Context for free testosteroneIf measuring free testosterone, use equilibrium dialysis or an accurate calculated estimate per Endocrine Society guidance; use laboratory lower limits until harmonized ranges established

Delayed male puberty age threshold

Delayed puberty cutoffPuberty is considered delayed when it has not started by age 14

Provider Requirements, Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required to establish medical necessity for subcutaneous testosterone pellet implants (Testopel). Ensure prior authorization is obtained before scheduling implantation to avoid claim denials.

Prior authorization required for Testopel pellet implantation
Verify member eligibility and benefits prior to authorization submission

Billing Rule

Coverage Coding Note

Testopel (testosterone) pellets are covered when medically necessary and coded appropriately. Subcutaneous estradiol pellets are investigational and not covered; submitting claims for estradiol pellets may result in denial.

Background and Context

Subcutaneous hormone pellets are solid implants placed under the skin (commonly in the lower abdomen or buttocks) that provide sustained drug release over approximately 3–6 months. The procedure is typically performed in a physician’s office under local anesthesia through a small incision for pellet insertion. Because pellets bypass first‑pass gastrointestinal and hepatic metabolism, they can increase bioavailability and provide steady hormone delivery that may approximate endogenous production.

For estradiol specifically, the policy notes there are no FDA‑approved implantable estradiol pellet formulations in the United States and that available compounded formulations have produced unpredictable and fluctuating serum estrogen levels; the FDA has previously ended investigational programs for estrogen pellets citing concerns about release rates, dosing control, reversibility, and safety risks.

For testosterone, approved formulations such as Testopel (75 mg pellets) exist for replacement therapy in men with hypogonadism due to disorders of the testicles, pituitary gland, or brain. Pellet implantation, however, is less adaptable for dose adjustments than oral or intramuscular options, which necessitates careful dose estimation and laboratory monitoring when used for appropriate indications.

Key Definitions

ANDROGEN

DefinitionANDROGEN: A general term for male sex hormone.

ENDOGENOUS

DefinitionENDOGENOUS: Developing or originating within the body.

HYPOGONADISM

DefinitionHYPOGONADISM: An inadequate gonadal function, marked by deficiencies in the secretion of gonadal hormones and spermatogenesis.

MENOPAUSE

Policy Summary

PayerCapital Bluecross

PolicySubcutaneous Hormone Pellet Implants

Policy CodePolicy MP 2.345

Change TypeNo material change

Effective DateOct 1, 2025

Next Review DateN/A

SourceLink

On This Page

AAP range contextBoys normally start puberty between ages 9 and 14 (95% range) — threshold set at upper bound

Indication linkDelayed male puberty is an accepted indication for androgen therapy including subcutaneous testosterone implants when criteria met

Pellet dosing typical range

Typical adult total dosageUsual adult dosage 150–450 mg subcutaneously (total per administration)

Pellet dose ranges reportedPellet regimens referenced between 600–1,200 mg total (varies by BMI, age, pretreatment testosterone)

FDA/clinical pellet count guidanceFDA recommends 2–6 pellets every 3–6 months (protocols vary; number adjusted to maintain mid-normal serum testosterone)

Monitoring and timingAssess testosterone 2–4 weeks after implant, around 3 months, and re-check every 2–4 weeks as needed; many men require re-dosing by ~4–6 months

Covered procedure codes when medically necessary: 11980, S0189

Not covered / investigational: subcutaneous estradiol pellets — associated procedure codes may be denied

General billing note: code lists are not all-inclusive and coverage depends on member benefits

Step Therapy

Step-Therapy and Dosing Considerations

Step-therapy and dosing considerations: pellet dosing is less flexible than other testosterone formulations. Consider alternative FDA-approved testosterone formulations and document prior trials if clinically appropriate. Monitor dosing adjustments and document rationale when pellets are selected.

Pellet doses typically range from 600–1200 mg overall (2–6 pellets every 3–6 months per historical recommendations); dosing individualized by BMI, age, and baseline testosterone
Document prior use or contraindication of alternative testosterone formulations when applicable

Documentation Required

Required Laboratory Documentation and Monitoring

Providers must document required laboratory testing and ongoing monitoring to support medical necessity: obtain baseline and follow-up testosterone measurements as described in policy guidelines.

Baseline: two early morning total serum testosterone levels on different days below the laboratory reference range or < 300 ng/dL (one level <150 ng/dL may suffice for severe deficiency)
Free testosterone measurement considerations: use equilibrium dialysis or validated calculation from total testosterone, SHBG, and albumin per Endocrine Society guidance
Follow-up: first measurement 2–4 weeks after initial implant; subsequent levels around 3 months after implantation and periodically (every 2–4 weeks if adjusting) to guide re-implantation (re-implantation reasonable when total testosterone <400 ng/dL)
Do not measure testosterone during acute or subacute illness; document dates and results in the medical record

Denial Risk

Denial Triggers for Investigational Uses

Denial triggers: Subcutaneous estradiol pellet use is investigational — claims for estradiol pellet implantation are subject to denial. Other investigational uses of testosterone pellets (for example, treatment of age-related hypogonadism, sexual dysfunction without documented deficiency, or performance enhancement) may be denied.

Claims for subcutaneous estradiol pellets — investigational and not covered
Claims for implantable testosterone pellets without documented low testosterone and appropriate indications (primary or secondary hypogonadism, delayed male puberty, or gender-affirming therapy where applicable) risk denial
Claims lacking required laboratory documentation (see monitoring callout) or prior authorization are subject to denial

Note

Claim Finalization Note

Final processing of a claim is based on the member's benefit program and eligibility on the date of service, including applicable contract terms, benefit limitations, and exclusions. Medical policy determinations do not guarantee payment.

Payment subject to member benefit plan, eligibility, and medical necessity determination
Contact Provider Services or Member Services for questions about individual member coverage

DefinitionMENOPAUSE: Cessation of menstruation in the female (absence of menses for one year).

ContextMenopause usually results from normal aging but may follow bilateral oophorectomy or chemotherapy-induced ovarian failure.

ANDROGEN (duplicate)

Duplicate definition (source)ANDROGEN: A general term for male sex hormone.

ENDOGENOUS (duplicate)

Duplicate definition (source)ENDOGENOUS: Developing or originating within the body.

HYPOGONADISM (duplicate)

Duplicate definition (source)HYPOGONADISM: An inadequate gonadal function, marked by deficiencies in the secretion of gonadal hormones and spermatogenesis.

ORCHIECTOMY

DefinitionORCHIECTOMY: Excision of one or both testes.

SUBCUTANEOUS

DefinitionSUBCUTANEOUS: Under the skin.